Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Large Increase in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the target of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 16,753 shares, a growth of 26.7% from the January 15th total of 13,222 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 57,316 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily volume of 57,316 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.3% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC bought a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 51,710 shares of the company’s stock, valued at approximately $85,000. Kestra Private Wealth Services LLC owned approximately 0.84% of Chemomab Therapeutics as of its most recent SEC filing. 46.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CMMB has been the subject of several recent analyst reports. Zacks Research cut shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Chemomab Therapeutics in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $26.50.

Chemomab Therapeutics Trading Up 2.0%

NASDAQ:CMMB opened at $1.51 on Monday. Chemomab Therapeutics has a 12 month low of $1.42 and a 12 month high of $8.24. The stock has a market capitalization of $9.30 million, a price-to-earnings ratio of -0.51 and a beta of 0.56. The firm has a fifty day simple moving average of $1.81 and a two-hundred day simple moving average of $2.62.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.